

## View Now | How RDCA-DAP Can Help Inform Optimal Trial Design in Progressive Rare Disease



**RDCA-DAP<sup>®</sup>**  
Webinar Series

How RDCA-DAP Can Help Inform Optimal Trial Design in Progressive Rare Disease

July 21 | 12 pm ET

   
[c-path.org/programs/rdca-dap](https://c-path.org/programs/rdca-dap)

**When:** July 21, 2021, 12 p.m. ET

**Case Study:** Northstar Ambulatory Assessment as an outcome assessment in Duchenne muscular dystrophy

**Presenters:** Varun Aggarwal, PhD, Director, Statistical and Mathematical Medicine, Quantitative Medicine; Kevin Krudys, PhD, Office of Clinical Pharmacology, FDA

**RDCA-DAP team:** [Jeff Barrett](#), PhD, FCP, Senior Vice President, RDCA-DAP Lead; Alexandre Bétourné, PhD, PharmD, Scientific Director, RDCA-DAP

[View Now](#)